logo-loader
CelLBxHealth PLC

Angle PLC - ANGLE announces collaboration with Myriad Genetics

RNS Number : 9557V
Angle PLC
20 August 2025
 

For immediate release

20 August 2025

 

ANGLE plc ("the Company")

 

COLLABORATION WITH MYRIAD GENETICS 

 

Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test  

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has entered a collaboration with Myriad Genetics, Inc. (MYGN:NSQ), a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all.

 

Under the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix® system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay.

 

Further details of the agreement are confidential between the parties.

 

 

ANGLE Chief Executive, Andrew Newland, commented:

"We are delighted to be working with Myriad Genetics, a major player in tissue-based companion diagnostic tests, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system.  We look forward to working with Myriad Genetics to progress this collaboration which has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data."

 

 

 

For further information:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

 

 

Berenberg (NOMAD and Broker)

Toby Flaux, Ciaran Walsh, Milo Bonser

 

+44 (0) 20 3207 7800

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

 

+44 (0) 203 727 1000

+1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories.  Services include custom made assay development and clinical trial testing for pharma.

 

Over 110 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEALPNFFSSEFA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

London BTC Company, CelLBxHealth, Anglo Asian Mining, Galliford Try,...

London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. It's the company's fourth Nevada project and sits just 16 miles from the 16.4 million ounce Hycroft...

on 07/15/2026

3 min read